94-11625. Drug Export; Intraoral Fluoride Releasing Device  

  • [Federal Register Volume 59, Number 92 (Friday, May 13, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-11625]
    
    
    [[Page Unknown]]
    
    [Federal Register: May 13, 1994]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    [Docket No. 94N-0165]
    
     
    
    Drug Export; Intraoral Fluoride Releasing Device
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing that 
    Southern BioSystems, Inc., has filed an application requesting approval 
    for the export of the human drug Intraoral Fluoride Releasing Device to 
    Italy.
    ADDRESSES: Relevant information on this application may be directed to 
    the Dockets Management Branch (HFA-305), Food and Drug Administration, 
    rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
    person identified below. Any future inquiries concerning the export of 
    human drugs under the Drug Export Amendments Act of 1986 should also be 
    directed to the contact person.
    
    FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug 
    Evaluation and Research (HFD-313), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-594-2073.
    
    SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
    the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
    provide that FDA may approve applications for the export of drugs that 
    are not currently approved in the United States. Section 802(b)(3)(B) 
    of the act sets forth the requirements that must be met in an 
    application for approval. Section 802(b)(3)(C) of the act requires that 
    the agency review the application within 30 days of its filing to 
    determine whether the requirements of section 802(b)(3)(B) have been 
    satisfied. Section 802(b)(3)(A) of the act requires that the agency 
    publish a notice in the Federal Register within 10 days of the filing 
    of an application for export to facilitate public participation in its 
    review of the application. To meet this requirement, the agency is 
    providing notice that Southern BioSystems, Inc., 110 40th St. North, 
    Birmingham, AL 35222, has filed an application requesting approval for 
    the export of the human drug Intraoral Fluoride Releasing Device to 
    Italy. Intraoral Fluoride Releasing Device in indicated for long-term 
    controlled release of fluoride to reduce dental caries. The application 
    was received and filed in the Center for Drug Evaluation and Research 
    on March 4, 1994, which shall be considered the filing date for 
    purposes of the act.
        Interested persons may submit relevant information on the 
    application to the Dockets Management Branch (address above) in two 
    copies (except that individuals may submit single copies) and 
    identified with the docket number found in brackets in the heading of 
    this document. These submissions may be seen in the Dockets Management 
    Branch between 9 a.m. and 4 p.m., Monday through Friday.
        The agency encourages any person who submits relevant information 
    on the application to do so by May 23, 1994, and to provide an 
    additional copy of the submission directly to the contact person 
    identified above, to facilitate consideration of the information during 
    the 30-day review period.
        This notice is issued under the Federal Food, Drug, and Cosmetic 
    Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
    Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
    Center for Drug Evaluation and Research (21 CFR 5.44).
    
        Dated: May 3, 1994.
     Stephanie R. Gray,
     Acting Director, Office of Compliance, Center for Drug Evaluation and 
    Research.
    [FR Doc. 94-11625 Filed 5-12-94; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
05/13/1994
Department:
Health and Human Services Department
Entry Type:
Uncategorized Document
Action:
Notice.
Document Number:
94-11625
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: May 13, 1994, Docket No. 94N-0165